{"id":1019085,"date":"2026-11-09T18:14:28","date_gmt":"2026-11-09T23:14:28","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-reports-third-quarter-2026-financial-results-and-announces-strategic-prioritization-plan\/"},"modified":"2026-11-09T18:14:28","modified_gmt":"2026-11-09T23:14:28","slug":"coherus-oncology-reports-third-quarter-2026-financial-results-and-announces-strategic-prioritization-plan","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/coherus-oncology-reports-third-quarter-2026-financial-results-and-announces-strategic-prioritization-plan\/","title":{"rendered":"Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan"},"content":{"rendered":"
\n

\n \u2013 Focus development efforts on tagmokitug\/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development \u2013\u00a0<\/em>\n <\/p>\n

\n \u2013 Deprioritize development of tagmokitug\/toripalimab in other indications to allocate resources toward advancing the lead indication<\/em>
\n \u2013<\/em>\n <\/p>\n

\n \u2013 Right-sizing reduces headcount by ~30%, aligning organization with forward-focused needs \u2013<\/em>\n <\/p>\n

\n \u2013 Reports LOQTORZI\u00ae net revenue of $14.0 million in Q3 2026 \u2013<\/em>\n <\/p>\n

\n \u2013 Conference call today at 5:00 p.m. Eastern Standard Time \u2013<\/em>\n <\/p>\n

REDWOOD CITY, Calif., Nov. 09, 2026 (GLOBE NEWSWIRE) — Coherus Oncology, Inc.<\/strong> (Nasdaq: CHRS) today reported financial results for the third quarter 2026 and provided an overview of recent business highlights.<\/p>\n

\u201cThe strategic prioritization of esophageal cancer as our best-in-disease focus for tagmokitug, together with the Transition Services Agreement wind-down and the toripalimab process transfer completion, provides an ideal opportunity to right-size the organization and deliver financial benefits that flow directly from this prioritization,\u201d said Denny Lanfear, Chief Executive Officer of Coherus Oncology. \u201cOver the next four or five quarters we will remain intensely focused on growing LOQTORZI market share in relation to chemo-only, an inferior therapeutic approach, and off-label IO, which has not demonstrated standard-of-care level of benefit for patients living with nasopharyngeal carcinoma. We believe this approach can provide a path to financial self-sufficiency.\u201d<\/p>\n

\u201cEsophageal cancers constitute difficult-to-treat tumors with significant unmet medical need. The compelling anti-tumor activity observed in both ESCC and EAC tumors suggests that Tregs are a critical driver of resistance. Importantly, we saw tagmokitug enhance PD-1\u2019s activity, demonstrate activity in PD-L1 negative tumors, and rescue PD-1 refractory patients,\u201d said Rosh Dias, M.D., Chief Medical Officer of Coherus Oncology. \u201cOur immediate next step is to align with the FDA on our plans to expand the signal observed in esophageal cancer, with an initial focus on the second-line setting. This represents the fastest path to market in this underserved patient population.\u201d<\/p>\n

\u201cThe financial benefits of right-sizing the organization and reducing the scope of our forward-focused efforts provide substantial and durable benefits to our operating model,\u201d said Bryan McMichael, Chief Financial Officer of Coherus Oncology. \u201cThese benefits will be realized over the next two quarters, lowering our core cash burn by $6 million to $7 million quarterly, which in turn lowers the quarterly LOQTORZI revenues required to cover core burn to $25 million to $30 million, down from $30 million to $35 million, as previously guided.\u201d<\/p>\n

\n RECENT BUSINESS HIGHLIGHTS<\/strong>\n <\/p>\n

\n LOQTORZI\u00ae (toripalimab-tpzi) Commercial Updates <\/strong>\n <\/p>\n